Intelligent Design of Targeted Radiomers to Unlock First-in-Class Oncology Targets COF-01 & ALT-01
- Expanding radiopharmaceutical reach by drugging first-in-class targets COF-01 and ALT-01
- Optimizing tumor delivery through intelligent ligand design and tunable pharmacokinetics
- Accelerating clinical translation with a data-driven selection and prioritization framework
New Company for 2026